← Back to Search

Exparel vs Marcaine for Pain Management After Knee Replacement

N/A

Waitlist Available

Research Sponsored by Rothman Institute Orthopaedics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

All patients at least 18 years old who have primary unilateral TKA for osteoarthritis performed at Thomas Jefferson University Hospital.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within first 30 days post-operatively

Awards & highlights

Study Summary

This trial is testing whether Exparel is better than Marcaine at controlling pain and reducing side effects related to narcotics while also considering patient satisfaction and outcomes measures. The investigators will also analyze whether the higher price of Exparel is worth it based on factors like decreased need for postoperative pain medication and physical therapy.

Who is the study for?

This trial is for adults over 18 who need a knee replacement due to osteoarthritis at Thomas Jefferson University Hospital. It's not for those with severe anesthesia risks, kidney or liver disease, certain drug allergies, low blood pressure history, extreme body weight issues, recent substance abuse, or chronic opioid use.Check my eligibility

What is being tested?

The study compares Exparel and Marcaine as pain management drugs after knee surgery. It looks at how well they control pain, affect narcotic use and side effects, patient satisfaction and recovery outcomes including hospital stay length and physical therapy needs.See study design

What are the potential side effects?

Possible side effects of Exparel and Marcaine include reactions at the injection site like swelling or pain; systemic reactions such as nausea or vomiting; nerve damage symptoms like numbness; allergic responses; and potential impact on heart rate.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am over 18 and had a knee replacement at Thomas Jefferson University Hospital due to arthritis.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within first 30 days post-operatively

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within first 30 days post-operatively

This trial's timeline: 3 weeks for screening, Varies for treatment, and within first 30 days post-operatively for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

2. Measure pain intensity score (pre and post-operatively) by visual analogue scale (VAS) method

Trial Design

2Treatment groups

Active Control

Group I: MarcaineActive Control1 Intervention

Group II: ExparelActive Control1 Intervention

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Rothman Institute OrthopaedicsLead Sponsor

121 Previous Clinical Trials

21,578 Total Patients Enrolled

Media Library

Marcaine Clinical Trial Eligibility Overview. Trial Name: NCT02060591 — N/A

Total Knee Replacement Research Study Groups: Marcaine, Exparel

Total Knee Replacement Clinical Trial 2023: Marcaine Highlights & Side Effects. Trial Name: NCT02060591 — N/A

Marcaine 2023 Treatment Timeline for Medical Study. Trial Name: NCT02060591 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there currently an enrollment period for participants in this trial?

"According to clinicaltrials.gov, this research has ceased enrollment for the time being; it was first listed on 1/1/2014 and most recently updated 2/11/2014. Nonetheless, 151 other trials are presently recruiting patients."

Answered by AI

How many patients have consented to participate in this experiment?

"This trial is no longer open for enrolment; it was initially published on the first of January and the last update occurred at 11th February. Currently, there are 41 active trials with total knee arthroplasty (TKA) seeking participants and 110 studies concerning Exparel that have yet to reach their recruitment goals."

Answered by AI

What is the typical purpose of administering Exparel?

"Exparel is a viable pharmacological option for the management of pernphigus, acute nonspecific tenosynovitis and general anesthesia."

Answered by AI

Has Exparel been vetted in other scientific experiments?

"Currently, Exparel is being tested in 110 live clinical studies with 18 trials at the third phase. While most of these are based near Philadelphia, Pennsylvania, there are a total of 147 different facilities running experiments for this treatment option."

Answered by AI

Recent research and studies

The Journal of ArthroplastyJournal

Periarticular Injection of Liposomal Bupivacaine Offers No Benefit over Standard Bupivacaine in Total Knee Arthroplasty: A Prospective, Randomized, Controlled Trial

Alijanipour, Pouya, Timothy L. Tan, Christopher N. Matthews, Jessica R. Viola, James J. Purtill, Richard H. Rothman, Javad Parvizi, and Matthew S. Austin. 2017. “Periarticular Injection of Liposomal Bupivacaine Offers No Benefit over Standard Bupivacaine in Total Knee Arthroplasty: A Prospective, Randomized, Controlled Trial”. The Journal of Arthroplasty. Elsevier BV. doi:10.1016/j.arth.2016.07.023.

clinicaltrials.govStudy

Comparison of Two Periarticular Injection Medications for Adjunctive Pain Management Following Total Knee Arthroplasty (TKA)

2014. "Comparison of Two Periarticular Injection Medications for Adjunctive Pain Management Following Total Knee Arthroplasty (TKA)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02060591.

All > Pennsylvania > Exparel